In a study conducted by Wiede et al. using a mice model, the deletion of PTPN2 in HER-2-specific CAR T cells led to an increase in LCK activation and cytokine-induced STAT-5 signaling, resulting in enhanced CAR T cell activation, homing to, and eradication of target HER-2+ mammary tumors in vivo [137]. This evidence concerns the gene ERBB2 and breast cancer.